Clinical and molecular patient characteristics
| Clinical feature . | Patients, n (%) . | DNA copy-number status at 6q15-16.1 . | ||
|---|---|---|---|---|
| Deletions, n (%) . | Balanced or gained, n (%) . | P . | ||
| Sex | >.999 | |||
| Male | 52 (71) | 7 (13) | 45 (87) | |
| Female | 21 (29) | 2 (10) | 19 (90) | |
| Age at diagnosis | .07 | |||
| Younger than 10 years | 44 (62) | 3 (7) | 41 (93) | |
| 10 years and older | 27 (38) | 6 (22) | 21 (78) | |
| Presenting WBC count at diagnosis | .16 | |||
| Less than 10 × 109/L | 6 (8) | 0 (0) | 6 (100) | |
| 10 × 109/L to less than 50 × 109/L | 21 (30) | 2 (10) | 19 (90) | |
| 50 × 109/L to less than 100 × 109/L | 9 (13) | 1 (11) | 8 (89) | |
| 100 × 109/L or more | 35 (49) | 6 (17) | 29 (83) | |
| T-cell immunophenotype* | .68 | |||
| Noncortical | 18 (26) | 3 (17) | 15 (83) | |
| Cortical | 52 (74) | 6 (12) | 46 (88) | |
| Prednisone response† | .72 | |||
| Good | 42 (62) | 5 (12) | 37 (88) | |
| Poor | 26 (38) | 4 (15) | 22 (85) | |
| NOTCH1 mutation status | .28 | |||
| Activating NOTCH1 mutation | 32 (44) | 2 (6) | 30 (94) | |
| Wild-type | 41 (56) | 7 (17) | 34 (83) | |
| MRD on day 33 | .66 | |||
| Favorable | 12 (25) | 1 (8) | 11 (92) | |
| Unfavorable | 36 (75) | 6 (17) | 30 (83) | |
| MRD on day 78 | .04 | |||
| Favorable | 25 (53) | 1 (4) | 24 (96) | |
| Unfavorable | 22 (47) | 6 (27) | 16 (73) | |
| Clinical feature . | Patients, n (%) . | DNA copy-number status at 6q15-16.1 . | ||
|---|---|---|---|---|
| Deletions, n (%) . | Balanced or gained, n (%) . | P . | ||
| Sex | >.999 | |||
| Male | 52 (71) | 7 (13) | 45 (87) | |
| Female | 21 (29) | 2 (10) | 19 (90) | |
| Age at diagnosis | .07 | |||
| Younger than 10 years | 44 (62) | 3 (7) | 41 (93) | |
| 10 years and older | 27 (38) | 6 (22) | 21 (78) | |
| Presenting WBC count at diagnosis | .16 | |||
| Less than 10 × 109/L | 6 (8) | 0 (0) | 6 (100) | |
| 10 × 109/L to less than 50 × 109/L | 21 (30) | 2 (10) | 19 (90) | |
| 50 × 109/L to less than 100 × 109/L | 9 (13) | 1 (11) | 8 (89) | |
| 100 × 109/L or more | 35 (49) | 6 (17) | 29 (83) | |
| T-cell immunophenotype* | .68 | |||
| Noncortical | 18 (26) | 3 (17) | 15 (83) | |
| Cortical | 52 (74) | 6 (12) | 46 (88) | |
| Prednisone response† | .72 | |||
| Good | 42 (62) | 5 (12) | 37 (88) | |
| Poor | 26 (38) | 4 (15) | 22 (85) | |
| NOTCH1 mutation status | .28 | |||
| Activating NOTCH1 mutation | 32 (44) | 2 (6) | 30 (94) | |
| Wild-type | 41 (56) | 7 (17) | 34 (83) | |
| MRD on day 33 | .66 | |||
| Favorable | 12 (25) | 1 (8) | 11 (92) | |
| Unfavorable | 36 (75) | 6 (17) | 30 (83) | |
| MRD on day 78 | .04 | |||
| Favorable | 25 (53) | 1 (4) | 24 (96) | |
| Unfavorable | 22 (47) | 6 (27) | 16 (73) | |
This group of patients is a subgroup of those who have been reported previously.2 P by Fisher exact test. WBC indicates white blood cell.
Noncortical: pro/pre (cyCD3+, CD7+, and CD1, and sCD3−), mature (CD1a−, sCD3+); cortical (CD1a+).
Good indicates fewer than 1000 leukemic blood blasts/μL on treatment day 8; and poor, equal to or more than 1000/μL.